盐酸帕洛诺司琼预防肿瘤化疗引起的恶心呕吐的疗效观察(1)
[摘要] 目的 评价盐酸帕洛诺司琼注射液预防肿瘤化疗引起的恶心呕吐的疗效。 方法 将我院2013年1月～2014年12月收治的肺癌和乳腺癌患者40例分为A组和B组，各20例，A组采用盐酸帕洛诺司琼首日给药0.25 mg，B组采用盐酸帕洛诺司琼在第1、3、5天给予0.25 mg/d。观察两组患者的疗效及不良反应情况。 结果 A组和B组在急性期恶心完全缓解率差异无统计学意义(55.0% vs 60.0%，P>0.05)，但在延迟期B组恶心完全缓解率明显高于A组(67.5% vs 52.5%，P<0.05)。A组和B组在急性期呕吐的完全缓解率差异无统计学意义(82.5% vs 80.0%， P>0.05)，但在延迟期B组呕吐完全缓解率明显高于A组(87.5% vs 70.0%，P<0.05)。两组不良反应总发生率分别为7.5%、10.0%，差异有统计学意义(P<0.05)。 结论 多次重复给予盐酸帕洛诺司琼较单剂量盐酸帕洛诺司琼，可以提高化疗患者的延迟期恶心呕吐完全缓解率，且两者不良反应相似。
[关键词] 盐酸帕洛诺司琼；化学治疗；恶心；呕吐
[中图分类号] R730.5 [文献标识码] B [文章编号] 1673-9701(2016)06-0066-03
Clinical observation of palonosetron hydrochloride injection in prevention of nausea and vomiting caused by cancer chemotherapy
YU Xiaoyun
Department of Internal Medicine of Oncology， Pulandian Center Hospital in Liaoning Province， Pulandian 116200， China
[Abstract] Objective To evaluate the curative effect of palonosetron hydrochloride injection in prevention of nausea and vomiting caused by cancer chemotherapy. Methods A total of 40 patients with lung cancer and breast cancer in our hospital from January 2013 to December 2014 were divided into group A and group B， 20 cases in each group， patients in group A were treated with palonosetron hydrochloride 0.25 mg on the first day， patients in group B were treated with palonosetron hydrochloride 0.25 mg/d on the first day， the third day and the fifth day. The curative effect and adverse reaction of the two groups were observed. Results There was no significant difference about the overall remission rates of nausea in the acute phase between group A and group B(55.0% vs 60.0%，P>0.05)， but the overall remission rates of nausea in the delay period in group B was significantly higher than in group A(67.5% vs 52.5%). There was no significant difference about the overall remission rates of vomiting in the acute phase between group A and group B (82.5% vs 80.0%，P>0.05)，but the overall remission rates of vomiting in the delay period in group B was significantly higher than in group A(87.5% vs 70.0%，P>0.05). The total incidence of adverse reaction in the two groups were respectively 7.5% and 10.0% the difference was statistically significant (P<0.05). Conclusion Compared with single dose， palonosetron hydrochloride repeatedly given can improve the overall remission rates of nausea and vomiting in the delay period in chemotherapy patients， and the incidence of adverse reaction is similar.
[Key words] Palonosetron hydrochloride； Chemotherapy； Nausea； Vomiting, 百拇医药(于小云)
[关键词] 盐酸帕洛诺司琼；化学治疗；恶心；呕吐
[中图分类号] R730.5 [文献标识码] B [文章编号] 1673-9701(2016)06-0066-03
Clinical observation of palonosetron hydrochloride injection in prevention of nausea and vomiting caused by cancer chemotherapy
YU Xiaoyun
Department of Internal Medicine of Oncology， Pulandian Center Hospital in Liaoning Province， Pulandian 116200， China
[Abstract] Objective To evaluate the curative effect of palonosetron hydrochloride injection in prevention of nausea and vomiting caused by cancer chemotherapy. Methods A total of 40 patients with lung cancer and breast cancer in our hospital from January 2013 to December 2014 were divided into group A and group B， 20 cases in each group， patients in group A were treated with palonosetron hydrochloride 0.25 mg on the first day， patients in group B were treated with palonosetron hydrochloride 0.25 mg/d on the first day， the third day and the fifth day. The curative effect and adverse reaction of the two groups were observed. Results There was no significant difference about the overall remission rates of nausea in the acute phase between group A and group B(55.0% vs 60.0%，P>0.05)， but the overall remission rates of nausea in the delay period in group B was significantly higher than in group A(67.5% vs 52.5%). There was no significant difference about the overall remission rates of vomiting in the acute phase between group A and group B (82.5% vs 80.0%，P>0.05)，but the overall remission rates of vomiting in the delay period in group B was significantly higher than in group A(87.5% vs 70.0%，P>0.05). The total incidence of adverse reaction in the two groups were respectively 7.5% and 10.0% the difference was statistically significant (P<0.05). Conclusion Compared with single dose， palonosetron hydrochloride repeatedly given can improve the overall remission rates of nausea and vomiting in the delay period in chemotherapy patients， and the incidence of adverse reaction is similar.
[Key words] Palonosetron hydrochloride； Chemotherapy； Nausea； Vomiting, 百拇医药(于小云)